NIAID has been at the forefront of cutting-edge biomedical research for decades. The work performed in its labs has furthered the understanding of the immune system and led to significant advances in the fields of immunology and infectious disease research. But it's a long path from basic scientific discoveries to approved vaccines, treatments, or diagnostic tools. NIAID is constantly pursuing collaborations with industry and academia to develop its technologies and materials into products that improve public health. The Technology Transfer and Intellectual Property Office facilitates collaborative relationships between NIAID investigators and the broader scientific community.
Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine
Arsenical Compounds as Therapeutics for Inflammatory Diseases
Anthrax Fusion Toxins With Improved Ability To Penetrate Cells
Multi-Specific Chimeric Antigen Receptors Against HIV
Complete list of Recent Licensing and Collaboration Opportunities
United States patent 9,012,618 was issued on April 21, 2015, for “Nucleic acids encoding modified Ebola virus glycoproteins with diminished cytotoxicity while retaining native antigenic structures.” NIAID inventor: Nancy Sullivan, Ph.D.
NIAID and MedImmune/AstraZeneca signed a cooperative research and development agreement (CRADA) to study the development of live, attenuated vaccines for pandemic influenza. NIAID principal investigator: Kanta Subbarao, M.B.B.S., M.P.H.
Complete list of Technology Development Recent Happenings
Last Updated May 21, 2015